Literature DB >> 2392503

Close correlation between behavioural response and binding in vivo for inhibitors of the rolipram-sensitive phosphodiesterase.

R Schmiechen1, H H Schneider, H Wachtel.   

Abstract

The antidepressant rolipram interacts in vitro with a binding site in brain tissue labeled by 3H-rolipram. A 3H-rolipram binding assay was employed in vivo to compare the affinity of rolipram-related compounds and reference phosphodiesterase (PDE) inhibitors with their potency in behavioural measures for potential antidepressant property. In two species, mice and rats, the potency of a number of compounds to antagonise reserpine-induced hypothermia (mice) and to induce head twitches (rats) was determined, as well as their potency to displace 3H-rolipram from forebrain binding sites in vivo. The treatment schedules for the two series of experiments were identical. Significant correlations between pharmacological effects and displacement of 3H-rolipram binding in vivo were observed in both species. Since the reference PDE inhibitors closely fit into the binding-pharmacological activity relationship, the PDE inhibitory properties of the substances involved are discussed.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2392503     DOI: 10.1007/bf02245738

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  17 in total

Review 1.  Dysbalance of neuronal second messenger function in the aetiology of affective disorders: a pathophysiological concept hypothesising defects beyond first messenger receptors.

Authors:  H Wachtel
Journal:  J Neural Transm       Date:  1989       Impact factor: 3.575

2.  The effect of a number of drugs with different pharmacological properties upon reserpine induced hypothermia in mice.

Authors:  H van Riezen; A Delver
Journal:  Arzneimittelforschung       Date:  1971-10

3.  Is phosphodiesterase inhibition a new mechanism of antidepressant action? A double blind double-dummy study between rolipram and desipramine in hospitalized major and/or endogenous depressives.

Authors:  D Bobon; M Breulet; M A Gerard-Vandenhove; F Guiot-Goffioul; G Plomteux; M Sastre-y-Hernández; M Schratzer; B Troisfontaines; R von Frenckell; H Wachtel
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1988

4.  Brain cAMP response to phosphodiesterase inhibitors in rats killed by microwave irradiation or decapitation.

Authors:  H H Schneider
Journal:  Biochem Pharmacol       Date:  1984-05-15       Impact factor: 5.858

5.  The ability of denbufylline to inhibit cyclic nucleotide phosphodiesterase and its affinity for adenosine receptors and the adenosine re-uptake site.

Authors:  C D Nicholson; S A Jackman; R Wilke
Journal:  Br J Pharmacol       Date:  1989-07       Impact factor: 8.739

6.  Stereospecific binding of the antidepressant rolipram to brain protein structures.

Authors:  H H Schneider; R Schmiechen; M Brezinski; J Seidler
Journal:  Eur J Pharmacol       Date:  1986-08-07       Impact factor: 4.432

7.  Autoradiographic mapping of a selective cyclic adenosine monophosphate phosphodiesterase in rat brain with the antidepressant [3H]rolipram.

Authors:  P Kaulen; G Brüning; H H Schneider; M Sarter; H G Baumgarten
Journal:  Brain Res       Date:  1989-12-04       Impact factor: 3.252

8.  Cyclic nucleotide phosphodiesterase in rat neostriatum: multiple isoelectric forms with similar kinetic properties.

Authors:  K P Minneman
Journal:  J Neurochem       Date:  1976-11       Impact factor: 5.372

9.  TVX 2706--a new phosphodiesterase inhibitor with antiinflammatory action. Biochemical characterization.

Authors:  T Glaser; J Traber
Journal:  Agents Actions       Date:  1984-10

10.  Rolipram versus imipramine in inpatients with major, "minor" or atypical depressive disorder: a double-blind double-dummy study aimed at testing a novel therapeutic approach.

Authors:  A Bertolino; D Crippa; S di Dio; K Fichte; G Musmeci; V Porro; V Rapisarda; M Sastre-y-Hernández; M Schratzer
Journal:  Int Clin Psychopharmacol       Date:  1988-07       Impact factor: 1.659

View more
  7 in total

1.  Molecular cloning and transient expression in COS7 cells of a novel human PDE4B cAMP-specific phosphodiesterase, HSPDE4B3.

Authors:  E Huston; S Lumb; A Russell; C Catterall; A H Ross; M R Steele; G B Bolger; M J Perry; R J Owens; M D Houslay
Journal:  Biochem J       Date:  1997-12-01       Impact factor: 3.857

2.  Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNF alpha generation from human monocytes by interacting with a 'low-affinity' phosphodiesterase 4 conformer.

Authors:  J E Souness; M Griffin; C Maslen; K Ebsworth; L C Scott; K Pollock; M N Palfreyman; J A Karlsson
Journal:  Br J Pharmacol       Date:  1996-06       Impact factor: 8.739

3.  Phosphodiesterase 4 in macrophages: relationship between cAMP accumulation, suppression of cAMP hydrolysis and inhibition of [3H]R-(-)-rolipram binding by selective inhibitors.

Authors:  J J Kelly; P J Barnes; M A Giembycz
Journal:  Biochem J       Date:  1996-09-01       Impact factor: 3.857

4.  Antidepressant-like effects of PDE4 inhibitors mediated by the high-affinity rolipram binding state (HARBS) of the phosphodiesterase-4 enzyme (PDE4) in rats.

Authors:  Han-Ting Zhang; Yu Zhao; Ying Huang; Chengjun Deng; Allen T Hopper; Michael De Vivo; Gregory M Rose; James M O'Donnell
Journal:  Psychopharmacology (Berl)       Date:  2006-04-04       Impact factor: 4.530

5.  Stereospecificity of rolipram actions on eosinophil cyclic AMP-specific phosphodiesterase.

Authors:  J E Souness; L C Scott
Journal:  Biochem J       Date:  1993-04-15       Impact factor: 3.857

6.  The involvement of type IV phosphodiesterases in cocaine-induced sensitization and subsequent pERK expression in the mouse nucleus accumbens.

Authors:  Amy C Janes; Kathleen M Kantak; James A Cherry
Journal:  Psychopharmacology (Berl)       Date:  2009-07-09       Impact factor: 4.530

7.  Insight into Inhibitory Mechanism of PDE4D by Dietary Polyphenols Using Molecular Dynamics Simulations and Free Energy Calculations.

Authors:  Veronika Furlan; Urban Bren
Journal:  Biomolecules       Date:  2021-03-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.